Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated（VRTX）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · VRTX · 截至 2026年6月8日
活动摘要
买入笔数
4
P-Purchase only
卖出笔数
84
近12个月
买卖比
0.05
Buy/Sell (by trades)
整体情绪
Vertex Pharmaceuticals Incorporated内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
VRTX 季度内部人买卖趋势
VRTX 内幕交易卖出 · VRTX 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · VRTX CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
VRTX 高管卖出股份 · VRTX 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| May 29, 2026 | Bozic Carmen EVP and CMO | Sale | 1,974 | $888K | Form 4 |
| May 15, 2026 | Bunnage Mark E. EVP, Chief Scientific Officer | Sale | 33 | $15K | Form 4 |
| May 15, 2026 | Bozic Carmen EVP and CMO | Sale | 1,354 | $614K | Form 4 |
| May 12, 2026 | Bozic Carmen EVP and CMO | Sale | 6,988 | $3.14M⚡ | Form 4 |
| May 1, 2026 | Upadhyay Suketu Director | Other | 796 | — | Form 4 |
| May 1, 2026 | Thornberry Nancy Director | Award | 472 | — | Form 4 |
| May 1, 2026 | Thornberry Nancy Director | Other | 398 | — | Form 4 |
| May 1, 2026 | Schneider Jennifer Director | Award | 472 | — | Form 4 |
| May 1, 2026 | Schneider Jennifer Director | Other | 796 | — | Form 4 |
| May 1, 2026 | MCKENZIE DIANA Director | Award | 943 | — | Form 4 |
| May 1, 2026 | MCKENZIE DIANA Director | Other | 796 | — | Form 4 |
| May 1, 2026 | Liu Joy EVP and Chief Legal Officer | Sale | 1,104 | $469K | Form 4 |
| May 1, 2026 | Garber Alan M Director | Award | 472 | — | Form 4 |
| May 1, 2026 | Bhatia Sangeeta N. Director | Award | 943 | — | Form 4 |
| May 4, 2026 | Bhatia Sangeeta N. Director | Sale | 318 | $135K | Form 4 |
| Apr 1, 2026 | Liu Joy EVP and Chief Legal Officer | Sale | 978 | $439K | Form 4 |
| Mar 27, 2026 | Bozic Carmen EVP and CMO | Sale | 2,329 | $1.05M⚡ | Form 4 |
| Mar 13, 2026 | Bozic Carmen EVP and CMO | Sale | 2,329 | $1.12M⚡ | Form 4 |
| Mar 11, 2026 | McKechnie Duncan EVP, Chief Commercial Officer | Sale | 2,633 | $1.31M⚡ | Form 4 |
| Mar 4, 2026 | McKechnie Duncan EVP, Chief Commercial Officer | Sale | 2,437 | $1.16M⚡ | Form 4 |
| Mar 2, 2026 | Liu Joy EVP and Chief Legal Officer | Sale | 892 | $442K | Form 4 |
| Feb 27, 2026 | Kewalramani Reshma CEO & President · Director | Sale | 400 | $192K | Form 4 |
| Feb 27, 2026 | Kewalramani Reshma CEO & President · Director | Sale | 120 | $58K | Form 4 |
| Feb 27, 2026 | Kewalramani Reshma CEO & President · Director | Sale | 240 | $116K | Form 4 |
| Feb 27, 2026 | Kewalramani Reshma CEO & President · Director | Sale | 2,510 | $1.22M⚡ | Form 4 |
McKechnie Duncan
EVP, Chief Commercial Officer
日期
Mar 11
股数
2,633
均价
$498.42
总金额
$1.31M ⚡
McKechnie Duncan
EVP, Chief Commercial Officer
日期
Mar 4
股数
2,437
均价
$475.30
总金额
$1.16M ⚡
Kewalramani Reshma
CEO & President · Director
日期
Feb 27
股数
400
均价
$479.75
总金额
$192K
Kewalramani Reshma
CEO & President · Director
日期
Feb 27
股数
240
均价
$482.84
总金额
$116K
Kewalramani Reshma
CEO & President · Director
日期
Feb 27
股数
2,510
均价
$487.13
总金额
$1.22M ⚡
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 VRTX 内幕交易
VRTX 内幕交易
Vertex Pharmaceuticals Incorporated（VRTX）内幕交易数据来源于公司内部人（包括Kewalramani Reshma (CEO & President · Director), Sachdev Amit (EVP Chief Patient & Ext Af Off), Bozic Carmen (EVP and CMO)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。VRTX内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Vertex Pharmaceuticals Incorporated机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
VRTX 内幕交易 · 5个问题Vertex Pharmaceuticals Incorporated（VRTX）的内部人包括高管和董事，如Kewalramani Reshma (CEO & President · Director), Sachdev Amit (EVP Chief Patient & Ext Af Off), Bozic Carmen (EVP and CMO)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026